Antibiotic Resistance Threats in the United States. Department of Health and Human Services, CDC; 2019, www.cdc.gov/drugresistance/Biggest-Threats.html.

Collaborators AR. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399:629–55.

Article  Google Scholar 

Fischbach MA, Walsh CT. Antibiotics for emerging pathogens. Science. 2009;325:1089–93.

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Liu T, Zhang Y, Wan Q. bacteremia among liver transplant recipients. Infect Drug Resist. 2018;11:2345–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Stoitsova SO, Braun Y, Ullrich MS, Weingart H. Characterization of the RND-type multidrug efflux pump MexAB-OprM of the plant pathogen Pseudomonas syringae. Appl Environ Microbiol. 2008;74:3387–93.

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Ferrer-Espada R, Shahrour H, Pitts B, Stewart PS, Sánchez- Gómez S, Martínez-de-Tejada G. A permeability-increasing drug synergizes with bacterial efflux pump inhibitors and restores susceptibility to antibiotics in multi-drug resistant Pseudomonas aeruginosa strains. Sci Rep. 2019;9:3452.

Article  ADS  PubMed  PubMed Central  Google Scholar 

Kimishima A, Sakai K, Honsho M, Wasuwanich P, Matsui H, Watanabe Y, et al. An efflux pump deletion mutant enabling the discovery of a macrolide as an overlooked anti-P. aeruginosa active compound. J Antibiot. 2023;76:301–3.

Article  CAS  Google Scholar 

Kimishima A, Sakai K, Honsho M, Matsui H, Wasuwanich P, Watanabe Y, et al. A combination strategy of a semisynthetic macrolide, 5-O-mycaminosyltylonolide with polymyxin B nonapeptide for multi-drug resistance P. aeruginosa. J Antibiot. 2023;76:499–501.

Article  CAS  Google Scholar 

Phan LT, Qui YL, Or YS, Vo NH, Jian T, Hou Y, Busuyek M. 23-O-Substituted 5-O-Mycaminosyltylonide Derivatives. 2003, Patent WO03089446A2.

Renau TE, Léger R, Flamme EM, Sangalang J, She MW, Yen R, et al. Inhibitors of efflux pumps in Pseudomonas aeruginosa potentiate the activity of the fluoroquinolone antibacterial levofloxacin. J Med Chem. 1999;42:4928–31.

Article  CAS  PubMed  Google Scholar 

Niki Y, Hanaki H, Yagisawa M, Kohno S, Aoki N, Watanabe A, et al. The first nationwide surveillance of bacterial respiratory pathogens conducted by the Japanese Society of Chemotherapy. Part 1: a general view of antibacterial susceptibility. J Infect Chemother. 2008;14:279–90.

Article  CAS  PubMed  Google Scholar 

Takesue Y, Watanabe A, Hanaki H, Kusachi S, Matsumoto T, Iwamoto A, et al. Nationwide surveillance of antimicrobial susceptibility patterns of pathogens isolated from surgical site infections (SSI) in Japan. J Infect Chemother. 2012;18:816–26.

Article  CAS  PubMed  Google Scholar 

Ishikawa K, Hamasuna R, Uehara S, Yasuda M, Yamamoto S, Hayami H, et al. Japanese nationwide surveillance in 2011 of antibacterial susceptibility patterns of clinical isolates from complicated urinary tract infection cases. J Infect Chemother. 2015;21:623–33.

Article  PubMed  Google Scholar 

Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing. 32nd ed. 2022. Available from: https://clsi.org.

Leber AL, et al. Clinical Microbiology Procedures Handbook. 1-3, 4th ed. Washinngton, DC: ASM Press. American Society for Microbiology; 2016.